# Cost of goods and gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète → for drugs versus devices
A single Lipitor tablet cost Pfizer roughly a few cents to manufacture at peak scale, yet sold for a dollar or more per pill. That gap is the entire logic of the pharma business model. Now hold that thought against a spinal implant that costs thousands to build and ships with a sales rep in the operating room. Same healthcare sector, wildly different economics. This lesson shows you the calculations behind why.
Gross marginGross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.
COGS (Cost of Goods Sold) is what it costs to physically make and deliver the product: raw materials, factory labor, plant overhead, quality control, and (for devices) the physical components. It excludes R&D, sales, marketing, and admin. Those live below the gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète → line.
Worked example. A drug sells for $100 per unit and costs $8 to make.
That 92% is the money left to fund everything else: the multi-year clinical trials, the sales force, the shareholders.
A small molecule is a chemically synthesized drug with a simple, stable structure (aspirin, statins, most pills you know). Once the chemistry is worked out, making more is cheap. The active ingredient is often pennies per dose. Packaging and tableting add a little more.
The expensive part already happened: the R&D and the trials. That is a sunk cost that never touches COGS. So the marginal cost of pill number ten million is tiny.
Rough benchmark (estimate): large-cap pharma with small-molecule-heavy portfolios often report gross margins in the 70% to 85% range at the corporate level, with individual blockbuster products well above 90%. The corporate figure is dragged down by royalties, lower-margin legacy products, and inventory write-offs. You can verify any public company's real numbers in their SEC filings via EDGAR (free).
COGS barely changes when a drug loses patent protection, but price collapses. A generic version can sell for a fraction of the branded price. Same cheap COGS, but now a $100 drug sells for $4. The margin math still works (generics run positive gross margins), but the absolute profit evaporates. This is why the calculation matters: high margin percentage does not equal high margin dollars.
A medical device is physical hardware. A Class III device (the FDA's highest-risk category, covering life-sustaining or implantable products like pacemakers, heart valves, and spinal hardware) carries real material and manufacturing costs on every single unit.
Every device shipped consumes:
Unlike a pill, you cannot make the ten-millionth unit for pennies. The marginal cost stays stubborn.
Rough benchmark (estimate): large medtech companies typically report corporate gross margins around 55% to 70%. High-end implantables and diagnostics with proprietary consumables sit at the top of that range; commodity hardware sits lower.
A device sells for $5,000 and costs $1,750 to build and package.
Now compare the two side by side.
| Product type | Price (example) | COGS (example) | Gross marginGross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète → |
|---|---|---|---|
| Small-molecule drug | $100 | $8 | 92% |
| Class III device | $5,000 | $1,750 | 65% |
Same industry. A 27-point margin gap driven entirely by physical manufacturing.
Many device companies deliberately accept thin margins on the capital equipment (the "razor") to lock in high-margin recurring consumables (the "blades"). A surgical robot may sell near cost, but every procedure needs proprietary single-use instruments at rich margins. Intuitive Surgical built its economics on exactly this recurring-consumables model. When you read a device company, always split the revenue: instrument margin versus consumable margin tells the real story.
A biologic is a large, complex molecule produced inside living cells (think antibodies like Humira or Keytruda), not chemically synthesized. Manufacturing means growing cells in bioreactors, purifying the output, and keeping everything cold. This is far more expensive than pressing a tablet.
Even so, at scale, blockbuster biologics still reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.Voir la définition complète → high gross margins, often 80%+ (estimate), because the price per dose is very high and volumes are large. The COGS is bigger in absolute dollars but small relative to price.
Cell therapies (for example CAR-T, where a patient's own immune cells are extracted, re-engineered, and reinfused) and one-time gene therapies flip the assumptions entirely.
Why COGS explodes:
Per-patient manufacturing cost estimates for approved CAR-T therapies have been widely cited in the low-to-mid tens of thousands of dollars or more, against list prices that can run several hundred thousand dollars per treatment. So the gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.Voir la définition complète → percentage can still look healthy, but the manufacturing operation looks nothing like a pharma plant. It resembles a network of specialized labs.
The financial takeaway: for cell therapy, COGS is a scaling and operations problem, not a chemistry problem. Analysts watch manufacturing success rate and cost per delivered dose as first-order metrics, because a failed batch means zero revenue on a patient-specific run.
Vérification des acquis
1. Why do individual blockbuster small-molecule drugs achieve gross margins above 90%?
2. A company's corporate-level gross margin is 78%, but its flagship drug alone runs above 90%. What best explains this gap?
3. Two products sell at the same price, but Product A has a 90% gross margin and Product B has a 40% gross margin. What does this most directly tell you?
4. Select ALL correct answers about what is INCLUDED in Cost of Goods Sold (COGS).
Sélectionnez toutes les réponses correctes.
5. Select ALL correct answers explaining why a spinal implant would show much lower gross margins than a small-molecule pill.
Sélectionnez toutes les réponses correctes.
Percentage alone lies. Train yourself to ask three questions.
1. Margin dollars, not just margin percent. A 92% margin on a niche drug with $20M revenue produces less cash than a 65% margin on a $2B device franchise. Multiply it out.
2. What is inside COGS? Watch for inventory write-offs (destroyed or expired stock), royalty payments to partners (some companies book these in COGS, dragging margin down), and capacity underutilization (a half-empty biologics plant still costs money, crushing early-stage margins).
3. Trajectory. A young cell-therapy company may post ugly gross margins because volumes are tiny and the plant is new. The investment question is whether margin expands as volume scales. For small molecules there is little scale story left; for cell therapy the entire thesis is margin improvement over time.
For device companies with the razor-and-blade model, compute margin by segment, not blended. Suppose:
Blended = (40M minus 14M) / 40M = 65%. But the consumables line is the durable engine. If you only saw the blended 65%, you would miss that 75% of revenue comes from the high-margin recurring stream. Always disaggregate.
Treat these as typical corporate-level ranges, not precise figures. Always confirm against a company's own filings.